Skip to main content
. 2024 Jun 24;14:1361420. doi: 10.3389/fonc.2024.1361420

Figure 3.

Figure 3

Estimated Kaplan-Meier and the impact of treatment (with or without 1–2 prior lines of treatment for patients with intrahepatic cholangiocarcinoma). Two-year rates of survival with and without prior treatment were 72 and 56%, respectively. Survival was calculated from the first day of treatment with GFLIO. At the time of progression, docetaxel/mitomycin C were added, and then subsequently cetuximab and then bevacizumab.